WO2022191551A1 - Composition comprising cannabigerol - Google Patents
Composition comprising cannabigerol Download PDFInfo
- Publication number
- WO2022191551A1 WO2022191551A1 PCT/KR2022/003210 KR2022003210W WO2022191551A1 WO 2022191551 A1 WO2022191551 A1 WO 2022191551A1 KR 2022003210 W KR2022003210 W KR 2022003210W WO 2022191551 A1 WO2022191551 A1 WO 2022191551A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hair
- composition
- lotion
- ginseng
- extract
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 title claims abstract description 28
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 title claims abstract description 27
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 41
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims abstract description 40
- ZYTMANIQRDEHIO-KXUCPTDWSA-N isopulegol Chemical compound C[C@@H]1CC[C@@H](C(C)=C)[C@H](O)C1 ZYTMANIQRDEHIO-KXUCPTDWSA-N 0.000 claims abstract description 34
- 229930182490 saponin Natural products 0.000 claims abstract description 32
- 235000008434 ginseng Nutrition 0.000 claims abstract description 31
- 150000007949 saponins Chemical class 0.000 claims abstract description 31
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 30
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 30
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 26
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 21
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 20
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 20
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims abstract description 20
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 20
- 229960005305 adenosine Drugs 0.000 claims abstract description 20
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 20
- SVURIXNDRWRAFU-OGMFBOKVSA-N cedrol Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@@H]1[C@@](O)(C)CC2 SVURIXNDRWRAFU-OGMFBOKVSA-N 0.000 claims abstract description 20
- 229940026455 cedrol Drugs 0.000 claims abstract description 20
- PCROEXHGMUJCDB-UHFFFAOYSA-N cedrol Natural products CC1CCC2C(C)(C)C3CC(C)(O)CC12C3 PCROEXHGMUJCDB-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940059958 centella asiatica extract Drugs 0.000 claims abstract description 20
- SVURIXNDRWRAFU-UHFFFAOYSA-N juniperanol Natural products C1C23C(C)CCC3C(C)(C)C1C(O)(C)CC2 SVURIXNDRWRAFU-UHFFFAOYSA-N 0.000 claims abstract description 20
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 20
- 229940101267 panthenol Drugs 0.000 claims abstract description 20
- 235000020957 pantothenol Nutrition 0.000 claims abstract description 20
- 239000011619 pantothenol Substances 0.000 claims abstract description 20
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 20
- 239000011718 vitamin C Substances 0.000 claims abstract description 20
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 19
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 19
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 19
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 19
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 19
- 239000011570 nicotinamide Substances 0.000 claims abstract description 19
- 230000002087 whitening effect Effects 0.000 claims abstract description 19
- 241000241413 Propolis Species 0.000 claims abstract description 18
- 229940069949 propolis Drugs 0.000 claims abstract description 18
- 239000001871 (1R,2R,5S)-5-methyl-2-prop-1-en-2-ylcyclohexan-1-ol Substances 0.000 claims abstract description 17
- 229940095045 isopulegol Drugs 0.000 claims abstract description 17
- ZYTMANIQRDEHIO-UHFFFAOYSA-N neo-Isopulegol Natural products CC1CCC(C(C)=C)C(O)C1 ZYTMANIQRDEHIO-UHFFFAOYSA-N 0.000 claims abstract description 17
- 241000208340 Araliaceae Species 0.000 claims abstract 5
- 239000002537 cosmetic Substances 0.000 claims description 25
- 239000006210 lotion Substances 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 239000000443 aerosol Substances 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 108090000991 Aquaporin 3 Proteins 0.000 claims description 12
- 102000004363 Aquaporin 3 Human genes 0.000 claims description 11
- 102000003425 Tyrosinase Human genes 0.000 claims description 10
- 108060008724 Tyrosinase Proteins 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 230000014509 gene expression Effects 0.000 claims description 10
- -1 pack Substances 0.000 claims description 10
- 239000007921 spray Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 241000195940 Bryophyta Species 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 235000011929 mousse Nutrition 0.000 claims description 8
- 239000000686 essence Substances 0.000 claims description 7
- 239000003599 detergent Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 244000062730 Melissa officinalis Species 0.000 claims description 5
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 5
- 239000000865 liniment Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 239000002453 shampoo Substances 0.000 claims description 4
- 230000001256 tonic effect Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 abstract description 16
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 210000003491 skin Anatomy 0.000 description 43
- 235000017709 saponins Nutrition 0.000 description 28
- 240000004371 Panax ginseng Species 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 18
- 239000000284 extract Substances 0.000 description 16
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 11
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 244000146462 Centella asiatica Species 0.000 description 3
- 235000004032 Centella asiatica Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- PVLHOJXLNBFHDX-XHJPDDKBSA-N Panaxadiol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(CC[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 PVLHOJXLNBFHDX-XHJPDDKBSA-N 0.000 description 1
- SYFJYASKXNAXKC-UHFFFAOYSA-N Panaxadiol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CCC34C SYFJYASKXNAXKC-UHFFFAOYSA-N 0.000 description 1
- QFJUYMMIBFBOJY-UXZRXANASA-N Panaxatriol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(C[C@@H](O)[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 QFJUYMMIBFBOJY-UXZRXANASA-N 0.000 description 1
- VIXIMKLMEZTTTC-UHFFFAOYSA-N Panaxatriol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C VIXIMKLMEZTTTC-UHFFFAOYSA-N 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000109329 Rosa xanthina Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 101150105997 aop3 gene Proteins 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000002479 balanitis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- RLDVZILFNVRJTL-IWFVLDDISA-N ginsenoside Rd Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RLDVZILFNVRJTL-IWFVLDDISA-N 0.000 description 1
- NJUXRKMKOFXMRX-JJFYIABZSA-N ginsenoside rg5 Chemical compound CC(C)=CC\C=C(\C)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NJUXRKMKOFXMRX-JJFYIABZSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
- A61K8/988—Honey; Royal jelly, Propolis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Definitions
- the present invention cannabigerol (Cannabigerol); and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, Ginseng saponin, and one or more selected from the group consisting of propolis; a composition comprising, specifically, for moisturizing the skin including the composition as an active ingredient; for anti-inflammatory or skin soothing; Or it relates to a composition for whitening.
- Cannabigerol is a trace amount of active ingredient that can be obtained from the seeds of cannabis sativa. Cannabigerol is not a psychotropic substance and is known to have various effects.
- the present inventors have prepared cannabigerol; isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, When combined with one or more selected from the group consisting of vitamin C (vitamin C), panthenol, adenosine, cedrol, ginseng saponin, and propolis, HAS than using each component alone
- vitamin C vitamin C
- panthenol panthenol
- adenosine cedrol
- ginseng saponin ginseng saponin
- propolis HAS than using each component alone
- the present invention was completed by confirming that -2 (Hyaluronan Synthase 2) or AQP3 (Aquaporin 3) expression increase, NO production inhibition, and tyrosinase activity inhibition effects were significantly superior.
- the present invention is a cosmetic, for a quasi-drug composition, cannabigerol (Cannabigerol); and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides a composition comprising ginseng saponin, and one or more selected from the group consisting of propolis as an active ingredient.
- cannabigerol (Cannabigerol); and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides a skin moisturizing, anti-inflammatory or skin soothing, or skin whitening method comprising the step of treating the skin with a composition comprising ginseng saponin, and propolis as an active ingredient.
- cannabigerol (Cannabigerol); and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides a skin moisturizing, anti-inflammatory or skin soothing, or skin whitening method comprising administering to a subject a composition comprising ginseng saponin, and propolis as an active ingredient.
- skin moisturizing, anti-inflammatory or skin soothing, or skin whitening cosmetic In order to achieve the above object, skin moisturizing, anti-inflammatory or skin soothing, or skin whitening cosmetic; Or quasi-drugs; Cannabigerol for manufacturing; and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides the use of a composition comprising ginseng saponin, and propolis as an active ingredient.
- composition according to the present invention has an effect of increasing the expression of HAS-2 or AQP3, inhibiting the production of NO, and inhibiting tyrosinase activity, and has a synergistic effect due to the combination of the present invention, as a cosmetic or quasi-drug composition can be used effectively.
- Increased expression of HAS-2 or AQP3, inhibition of NO production, and inhibition of tyrosinase activity are all more effective than cannabigerol alone, isopulegol, ginseng extract, centella asiatica extract, niacinamide (niacinamide), hyaluronic acid (hyaluronic acid), vitamin C (vitamin C), panthenol (panthenol), adenosine (adenosine), cedrol (cedrol), one or more selected from the group consisting of ginseng saponin and propolis; It was confirmed that a synergistic effect occurred when combined with
- the present invention cannabigerol (Cannabigerol); and
- cannabigerol (Cannabigerol); and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides a skin moisturizing, anti-inflammatory or skin soothing, or skin whitening method comprising the step of treating the skin with a composition comprising ginseng saponin, and propolis as an active ingredient.
- cannabigerol (Cannabigerol); and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides a skin moisturizing, anti-inflammatory or skin soothing, or skin whitening method comprising administering to a subject a composition comprising ginseng saponin, and propolis as an active ingredient.
- the active ingredients (Cannabigerol, isopulegol, ginseng extract, Centella asiatica extract, niacinamide, hyaluronic acid, vitamin C (vitamin C), panthenol (panthenol), Adenosine (adenosine), cedrol (cedrol), ginseng saponin, and propolis) Legally permitted commercial products or commercial ingredients of the active ingredient may be used.
- the "extract" of the present invention is an extract obtained by the extraction treatment of the plant material, a diluted or concentrated liquid of the extract, a dried product obtained by drying the extract, a prepared or purified product of the extract, or a mixture thereof, such as the extract itself and extracts of all formulations that can be formed using the extract.
- the extract of the present invention may be prepared and used in the form of a dry powder after extraction.
- any part of ginseng or Centella asiatica such as an outpost, leaf, root, fruit, stem, etc. of ginseng or Centella asiatica may be used.
- the "ginseng saponin” of the present invention is a saponin present in the ginseng extract before purification, and refers to all of the saponin contained in ginseng, a substance represented by saponin, a substance to be changed to saponin, or a substance presumed to be saponin.
- the saponins contained in ginseng are panaxadiol-based saponins (Ra1, G-Ra2, G-Ra3, G-Rb1, G-Rb2, Rb3, G-Re, G-Rd, G-Rs1, G-Rs2, Rg3 ( 20 S), G-Rg3(20R), G-Rh2, G-Rs3, Rs4, G-Rg5, G-F4,Q-R1, N-R4, Rg6, etc.)
- Panaxatriol-based saponins Ros, Rf , Rg1, Rg2(20 S), Rg2(20 R), Rh1(20 S), Rh2(20 R), 20-glc-Rf, N-R1, Rh4, Rf2, etc.
- oleic saponins G-R, etc.
- G-R, etc. etc.
- the ginseng saponin of the present invention may be a mixture of several types of ginseng saponins mentioned above or not mentioned, or may be a single type of ginseng saponin, and ginsenoside, pseudoginsenoside, or its It may be other ginseng saponins.
- the composition may be a cosmetic or quasi-drug.
- the cosmetics include lotion, essence, lotion, cream, pack, gel, powder, foundation, balm, ointment, detergent, hair shampoo, hair tonic, hair conditioner, hair lotion, hair nourishing lotion, hair treatment, hair essence , hair pack, hair liquid, non-aerosol mousse, non-aerosol spray, aerosol mousse or aerosol spray formulation, but is not limited thereto.
- “Moisturizing skin” of the present invention means to increase the feeling of moisture in the skin and to maintain a moist state by suppressing moisture loss.
- the skin moisturizing effect was confirmed by increasing the expression of HAS-2 (Hyaluronan Synthase 2) or AQP3 (Aquaporin 3).
- composition may have an effect of increasing the expression of HAS-2 or AQP3.
- anti-inflammatory refers to inhibiting inflammation, and the inflammation is one of the defense responses of a living tissue to a certain stimulus, and refers to a complex lesion that combines three types: tissue deterioration, circulatory disorder and exudation, and tissue proliferation. More specifically, inflammation is part of innate immunity, and as in other animals, human innate immunity recognizes patterns on the surface of cells that are specific to pathogens. Phagocytes recognize cells with such a surface as non-self and attack pathogens. If pathogens break through the body's physical barriers, an inflammatory response occurs. The inflammatory response is a non-specific defense action that creates a hostile environment for microorganisms that invade the wound site.
- the white blood cells responsible for the early stage immune response flock and express cytokines. Therefore, the expression level of intracellular cytokines is an indicator of inflammatory response activation.
- skin diseases associated with inflammation include atopic dermatitis, psoriasis, erythematous diseases triggered by radiation, chemicals, burns, etc., acid burns, bullous dermatosis, lichenoid type disease, itching due to allergy, seborrheic eczema, acne on roses, pemphigus vulgaris, erythema multiforme, erythema nodosum, balanitis, vulvitis, inflammatory hair loss such as alopecia areata, cutaneous T-cell lymphoma, and the like.
- the anti-inflammatory effect of the present invention for example, it may have an effect of improving skin troubles such as acne.
- the anti-inflammatory hair loss such as alopecia areata, cutaneous T-cell lymphoma, and the like.
- skin soothing means alleviating or reducing inflammation, or itching, redness, pain, burning, or swelling caused by inflammation.
- the skin soothing may mean a skin soothing effect by reducing or inhibiting inflammation.
- the composition may have an effect of inhibiting the production of NO.
- Whitening of the present invention means not only to brighten skin tone by inhibiting the synthesis of melanin, but also to inhibit or prevent melanin deposition (hyperpigmentation), to relieve or to relieve freckles caused by UV rays, hormones, or heredity. It means any action that improves.
- melanin deposition hyperpigmentation
- tyrosinase activity was confirmed.
- the composition may have a tyrosinase activity inhibitory effect.
- the "cosmetics composition” of the present invention may be in the form of general emulsified formulations and solubilized formulations.
- lotions such as flexible lotions or nourishing lotions, emulsions such as facial lotions and body lotions, creams such as nourishing creams, moisture creams, and eye creams, essences, cosmetic ointments, balms, sprays, gels, packs, sunscreens , makeup base, liquid type, solid type or spray type foundation, powder, cleansing cream, cleansing lotion, makeup remover such as cleansing oil, cleansing agent such as cleansing foam, soap, body wash, etc., but is limited thereto it's not going to be
- the cosmetic includes a fatty substance, an organic solvent, a solubilizer, a thickening agent and a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, Ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any conventionally used in cosmetics It may contain adjuvants commonly used in the field of cosmetology such as other ingredients of
- the cosmetic formulation may include a relatively high concentration of the composition of the present invention in the case of a wash-off type cosmetic such as a makeup remover or a detergent in which the active ingredient stays on the skin within a short period of time.
- a wash-off type cosmetic such as a makeup remover or a detergent
- leave-on type cosmetics such as lotions, emulsions, creams, and essences
- the composition of the present invention at a lower concentration than the wash-off type cosmetics. would be free to include.
- the composition comprises 0.000001% to 10% by weight (preferably 0.000001% to 1% by weight) of the composition of the present invention based on the total weight of the composition.
- composition of the present invention contains less than 0.000001% by weight of the composition of the present invention, sufficient moisturizing, anti-inflammatory or skin soothing and whitening effects cannot be expected, and when it contains more than 10% by weight, unwanted reactions such as allergies This is to prevent this from occurring or there may be problems with skin safety.
- the "quasi-drug composition" of the present invention refers to an article that is used for the purpose of diagnosing, treating, alleviating, treating or preventing diseases of humans or animals, but has a milder effect on the human body than pharmaceuticals, and is not an instrument, machine or device among articles It means a composition for articles other than instruments, machines, or devices among articles used for the purpose of pharmacologically affecting the structure and function of humans or animals. Except for articles used for pharmaceutical purposes according to the Pharmaceutical Affairs Act, one embodiment may include, but is not limited to, external preparations for skin, personal care products, or preparations for internal use. Components and the like may be appropriately selected from conventional techniques known in the art.
- compositions of the present invention may be included in the composition of the present invention, preferably within a range not exceeding the maximum amount specified in the norms stipulated by the respective national governments.
- the cosmetic composition of the present invention may be added to the cosmetic composition of the present invention within a range that does not exceed the maximum amount specified in the Cosmetic Safety Act stipulated by each country or the “Cosmeceutical Safety Technical Specification” stipulated by the Chinese government. may be included.
- Ginseng (Panax ginseng) roots were extracted with 70% ethanol aqueous solution corresponding to 30 times the mass at room temperature for 3 days, and then filtered under reduced pressure. The filtered extract was concentrated and dried with a rotary evaporator (Buchi, Switzerland) to prepare an extract.
- Centella asiatica leaves were extracted with 70% ethanol aqueous solution corresponding to 30 times the mass at room temperature for 3 days, and then filtered under reduced pressure. The filtered extract was concentrated and dried with a rotary evaporator (Buchi, Switzerland) to prepare an extract.
- the prepared ginseng extract was extracted three times with a solvent in which equal amounts of water and saturated butanol were mixed, and the saturated butanol layers were combined and concentrated under reduced pressure using a rotary evaporator (Buchi, Switzerland).
- Example 1 Cannabigerol (CBG)
- Example 2 isopuregol
- Ginseng Extract Example 4 Centella asiatica extract
- Niacinamide Example 6 hyaluronic acid
- Example 7 vitamin c
- Example 8 panthenol
- Example 9 adenosine
- Example 10 cedrol
- Example 11 ginseng saponin
- Example 12 propolis
- Fibroblasts were seeded and cultured at a concentration of 2-5 x 10 4 cells/ml using DMEM (Dulbecco's Modified Eagle's Medium, Gibco) supplemented with 10% FBS (Fetal Bovine Serum) as a basal medium. After the cultured cells were transferred to DMEM medium not containing 10% FBS and calcium ions, Examples and Comparative Examples were treated alone or in combination at concentrations corresponding to Table 2 below and cultured for 24 hours.
- DMEM Dulbecco's Modified Eagle's Medium, Gibco
- FBS Fetal Bovine Serum
- TaqMan® Universal Master Mix II (Thermo Fisher, catalog number 4440043) with TaqMan® GeneExpression Assays (Thermo Fisher, catalog number 4331348), HAS2 primer (5'-CCCAAAATGTGAAGCTTGGT -3'), AQP3 primer (5'-AGACAGCCCCTTCAGGATTT-3' ) was used. Quantitative real time PCR was performed using the StepOnePlus® Realtime PCR System (Applied Biosystems, catalog number 4376600). The experimental results were calculated using the ⁇ Ct method based on the housekeeping gene Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 5'-TGCACCACCAACTGCTTAGC-3').
- Example 1 0.0001% 8.54 7.66
- Example 2 0.001% 2.25 29.81 11.40 25.14
- Example 3 0.01% 16.73 43.15 4.49 19.06
- Example 4 0.01% 15.00 32.95 2.51 20.93
- Example 5 0.001% 6.72 18.10 8.97 18.14
- Example 6 0.001% 6.41 33.79 3.78 12.76
- Example 7 0.001% 18.32 46.31 7.88 20.28
- Example 8 0.001% 3.17 16.95 2.48 20.53
- Example 9 0.001% 2.51 31.24 6.23 22.25
- Example 10 0.001% 8.06 22.67 0.98 16.59
- Example 11 0.01% 5.83 44.25 4.26 20.72
- Example 12 0.01% 6.09 35.54 4.90 23.94
- the NO production inhibitory effect was measured using a mouse macrophage cell line, Raw 264.7 cells (ATCC, catalog number CRL-2788). 10% FBS was added to DMEM and used as a growth medium. Raw264.7 cells were seeded at a concentration of 1 to 2 x 10 5 cells/ml and cultured in a 5% CO 2 incubator for one day. After removing the medium and starvation with a serum-free medium for 12 hours, Examples and Comparative Examples were treated alone or in combination at the concentrations corresponding to Table 3 below and pre-treated for 30 minutes.
- Example 1 sample number sample concentration NO production inhibition ability (%) Use of each sample alone Combination with Example 1 Comparative Example 1 0.00 Comparative Example 2 53.02
- Example 1 0.0001% 26.21
- Example 2 0.001% 13.50 59.04
- Example 3 0.01% 27.18 62.38
- Example 4 0.01% 27.53 57.73
- Example 5 0.001% 9.84 53.67
- Example 6 0.001% 24.09 60.74
- Example 7 0.001% 37.81 66.90
- Example 8 0.001% 21.42 57.97
- Example 9 0.001% 24.12 60.91
- Example 10 0.001% 12.47 52.72
- Example 11 0.01% 19.42 60.70
- Example 12 0.01% 25.63 57.80
- MNT-1 melanoma cells (ATCC, catalog number CRL-3450) were seeded in DMEM medium containing 10% FBS at a concentration of 1 to 2 x 10 5 cells/ml and cultured for 24 hours. Examples and Comparative Examples were treated alone or in combination on melanocytes cultured at the concentration corresponding to Table 4 below and cultured for 72 hours, and then the cells were recovered. After centrifugation at 13,000 rpm for 1 minute and removing the supernatant, 300 ⁇ l of 0.5% triton X-100 solution was added to the pellet to lyse the cells.
- Example 1 sample number sample concentration Tyrosinase activity (%) Use of each sample alone Combination with Example 1 Comparative Example 1 100 Comparative Example 2 57.94 Example 1 0.0001% 89.75 Example 2 0.001% 98.23 72.79 Example 3 0.01% 89.34 70.10 Example 4 0.01% 80.93 61.28 Example 5 0.001% 77.25 60.99 Example 6 0.001% 88.98 66.99 Example 7 0.001% 73.84 51.77 Example 8 0.001% 98.59 75.48 Example 9 0.001% 77.91 50.05 Example 10 0.001% 95.68 76.77 Example 11 0.01% 84.42 71.39 Example 12 0.01% 92.26 77.44
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Abstract
The present invention relates to a composition comprising: cannabigerol; and one or more selected from the group consisting of isopulegol, a ginseng extract, a Centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, Ginseng crude saponin, and propolis and, more particularly, to a skin moisturizing, anti-inflammatory or skin soothing, and whitening composition comprising the composition as an active ingredient. In addition, it was confirmed that in terms of all the moisturizing, anti-inflammatory or skin soothing, and whitening effects, the composition of the present invention had a synergistic effect when combined with one or more selected from the group consisting of isopulegol, a ginseng extract, a Centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, Ginseng crude saponin, and propolis, compared to cannabigerol alone.
Description
본 발명은 칸나비게롤(Cannabigerol); 및 아이소푸레골(isopulegol), 인삼 추출물, 병풀 추출물, 나이아신아마이드(niacinamide), 히알루론산(hyaluronic Acid), 비타민 C (vitamin C), 판테놀 (panthenol), 아데노신 (adenosine), 세드롤 (cedrol), 인삼조사포닌, 및 프로폴리스로 이루어진 군으로부터 선택된 하나 또는 그 이상;을 포함하는 조성물로, 구체적으로 상기 조성물을 유효성분으로 포함하는 피부 보습용; 항염 또는 피부 진정용; 또는 미백용 조성물에 관한 것이다.The present invention cannabigerol (Cannabigerol); and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, Ginseng saponin, and one or more selected from the group consisting of propolis; a composition comprising, specifically, for moisturizing the skin including the composition as an active ingredient; for anti-inflammatory or skin soothing; Or it relates to a composition for whitening.
최근 환경오염으로 인한 자외선 양의 증가, 서구화된 생활습관, 스트레스 등 피부건강을 위협하는 요인들이 증가하고 있다. 이들은 피부 오염, 건조, 트러블, 피부면역체계 이상 등을 유발하며, 결국 피부염, 거칠음, 급격한 노화 등을 야기한다.Recently, factors that threaten skin health such as an increase in the amount of UV rays due to environmental pollution, a westernized lifestyle, and stress are increasing. These cause skin contamination, dryness, troubles, and abnormal skin immune system, and eventually cause dermatitis, roughness, rapid aging, and the like.
기존에 알려진 피부 보습, 항염 또는 피부 진정, 또는 미백 등 효능을 갖는 유효 성분은 인체 적용 시 자극과 발적 등 안전성 문제를 일으킬 수 있다. 따라서 유효 성분은 안전성과 안정성에 따른 사용량의 제한이 있어 실질적인 개선 효과를 기대하기 어려운 문제가 있다.Existing active ingredients with efficacy such as skin moisturizing, anti-inflammatory or skin soothing, or whitening may cause safety problems such as irritation and redness when applied to the human body. Therefore, there is a problem in that it is difficult to expect a practical improvement effect because the amount of active ingredient is limited according to safety and stability.
칸나비게롤은 대마(Cannabis sativa)의 씨에서 얻을 수 있는 미량의 유효 성분으로, 대마 외에 식물의 발효, 미생물을 통한 물질 전환 등을 통해서 얻을 수도 있다. 칸나비게롤은 항정신성 물질이 아니며, 다양한 효능이 있는 것으로 알려져 있다.Cannabigerol is a trace amount of active ingredient that can be obtained from the seeds of cannabis sativa. Cannabigerol is not a psychotropic substance and is known to have various effects.
상기한 목적을 달성하기 위해, 예의 연구 노력한 결과, 본 발명자들은 칸나비게롤(Cannabigerol);을 아이소푸레골(isopulegol), 인삼 추출물, 병풀 추출물, 나이아신아마이드(niacinamide), 히알루론산(hyaluronic Acid), 비타민 C (vitamin C), 판테놀 (panthenol), 아데노신 (adenosine), 세드롤 (cedrol), 인삼조사포닌, 프로폴리스로 이루어진 군으로부터 선택된 하나 또는 그 이상과 조합하였을 때, 각 성분들의 단독 사용 보다 HAS-2(Hyaluronan Synthase 2) 또는 AQP3(Aquaporin 3)의 발현 증가, NO의 생성 억제, 타이로시네이즈(Tyrosinase) 활성 억제 효과가 월등히 뛰어난 것을 확인함으로써 본 발명을 완성하게 되었다.In order to achieve the above object, as a result of intensive research efforts, the present inventors have prepared cannabigerol; isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, When combined with one or more selected from the group consisting of vitamin C (vitamin C), panthenol, adenosine, cedrol, ginseng saponin, and propolis, HAS than using each component alone The present invention was completed by confirming that -2 (Hyaluronan Synthase 2) or AQP3 (Aquaporin 3) expression increase, NO production inhibition, and tyrosinase activity inhibition effects were significantly superior.
상기 목적을 달성하기 위하여, 본 발명은 화장료, 의약외품 조성물을 위한, 칸나비게롤(Cannabigerol); 및 아이소푸레골(isopulegol), 인삼 추출물, 병풀 추출물, 나이아신아마이드(niacinamide), 히알루론산(hyaluronic Acid), 비타민 C (vitamin C), 판테놀 (panthenol), 아데노신 (adenosine), 세드롤 (cedrol), 인삼조사포닌, 및 프로폴리스로 이루어진 군으로부터 선택된 하나 또는 그 이상;을 유효성분으로 포함하는 조성물을 제공한다.In order to achieve the above object, the present invention is a cosmetic, for a quasi-drug composition, cannabigerol (Cannabigerol); and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides a composition comprising ginseng saponin, and one or more selected from the group consisting of propolis as an active ingredient.
상기 목적을 달성하기 위하여, 칸나비게롤(Cannabigerol); 및 아이소푸레골(isopulegol), 인삼 추출물, 병풀 추출물, 나이아신아마이드(niacinamide), 히알루론산(hyaluronic Acid), 비타민 C (vitamin C), 판테놀 (panthenol), 아데노신 (adenosine), 세드롤 (cedrol), 인삼조사포닌, 및 프로폴리스를 유효성분으로 포함하는 조성물을 피부에 처리하는 단계를 포함하는, 피부 보습, 항염 또는 피부진정, 또는 피부 미백 방법을 제공한다.In order to achieve the above object, cannabigerol (Cannabigerol); and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides a skin moisturizing, anti-inflammatory or skin soothing, or skin whitening method comprising the step of treating the skin with a composition comprising ginseng saponin, and propolis as an active ingredient.
상기 목적을 달성하기 위하여, 칸나비게롤(Cannabigerol); 및 아이소푸레골(isopulegol), 인삼 추출물, 병풀 추출물, 나이아신아마이드(niacinamide), 히알루론산(hyaluronic Acid), 비타민 C (vitamin C), 판테놀 (panthenol), 아데노신 (adenosine), 세드롤 (cedrol), 인삼조사포닌, 및 프로폴리스를 유효성분으로 포함하는 조성물을 대상체에 투여하는 단계를 포함하는, 피부 보습, 항염 또는 피부진정, 또는 피부 미백 방법을 제공한다.In order to achieve the above object, cannabigerol (Cannabigerol); and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides a skin moisturizing, anti-inflammatory or skin soothing, or skin whitening method comprising administering to a subject a composition comprising ginseng saponin, and propolis as an active ingredient.
상기 목적을 달성하기 위하여, 피부 보습, 항염 또는 피부진정, 또는 피부 미백용 화장료; 또는 의약외품;을 제조하기 위한 칸나비게롤(Cannabigerol); 및 아이소푸레골(isopulegol), 인삼 추출물, 병풀 추출물, 나이아신아마이드(niacinamide), 히알루론산(hyaluronic Acid), 비타민 C (vitamin C), 판테놀 (panthenol), 아데노신 (adenosine), 세드롤 (cedrol), 인삼조사포닌, 및 프로폴리스를 유효성분으로 포함하는 조성물의 용도를 제공한다.In order to achieve the above object, skin moisturizing, anti-inflammatory or skin soothing, or skin whitening cosmetic; Or quasi-drugs; Cannabigerol for manufacturing; and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides the use of a composition comprising ginseng saponin, and propolis as an active ingredient.
본 발명에 따른 조성물은 HAS-2 또는 AQP3의 발현 증가, NO의 생성 억제, 타이로시네이즈(Tyrosinase) 활성 억제 효과가 있으며, 본 발명의 조합으로 인해 상승 효과가 있는 바, 화장료 또는 의약외품 조성물로 효과적으로 사용될 수 있다.The composition according to the present invention has an effect of increasing the expression of HAS-2 or AQP3, inhibiting the production of NO, and inhibiting tyrosinase activity, and has a synergistic effect due to the combination of the present invention, as a cosmetic or quasi-drug composition can be used effectively.
이하 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 실험예에서 확인한 것처럼, As confirmed in the experimental example of the present invention,
HAS-2 또는 AQP3의 발현 증가, NO의 생성 억제, 타이로시네이즈(Tyrosinase) 활성 억제 효과 모두 칸나비게롤(Cannabigerol) 단독일 때보다 아이소푸레골(isopulegol), 인삼 추출물, 병풀 추출물, 나이아신아마이드(niacinamide), 히알루론산(hyaluronic Acid), 비타민 C (vitamin C), 판테놀 (panthenol), 아데노신 (adenosine), 세드롤 (cedrol), 인삼조사포닌 및 프로폴리스로 이루어진 군으로부터 선택된 하나 또는 그 이상;과 조합하였을 때 시너지 효과가 발생함을 확인하였다.Increased expression of HAS-2 or AQP3, inhibition of NO production, and inhibition of tyrosinase activity are all more effective than cannabigerol alone, isopulegol, ginseng extract, centella asiatica extract, niacinamide (niacinamide), hyaluronic acid (hyaluronic acid), vitamin C (vitamin C), panthenol (panthenol), adenosine (adenosine), cedrol (cedrol), one or more selected from the group consisting of ginseng saponin and propolis; It was confirmed that a synergistic effect occurred when combined with
본 발명은 칸나비게롤(Cannabigerol); 및The present invention cannabigerol (Cannabigerol); and
아이소푸레골(isopulegol), 인삼 추출물, 병풀 추출물, 나이아신아마이드(niacinamide), 히알루론산(hyaluronic Acid), 비타민 C (vitamin C), 판테놀 (panthenol), 아데노신 (adenosine), 세드롤 (cedrol), 인삼조사포닌, 및 프로폴리스로 이루어진 군으로부터 선택된 하나 또는 그 이상;을 포함하는, 피부 보습용, 항염 또는 피부 진정용 또는 미백용 조성물을 제공한다.isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, ginseng It provides a composition for skin moisturizing, anti-inflammatory or skin soothing or whitening, including; saponin, and one or more selected from the group consisting of propolis.
다른 양태로서, 칸나비게롤(Cannabigerol); 및 아이소푸레골(isopulegol), 인삼 추출물, 병풀 추출물, 나이아신아마이드(niacinamide), 히알루론산(hyaluronic Acid), 비타민 C (vitamin C), 판테놀 (panthenol), 아데노신 (adenosine), 세드롤 (cedrol), 인삼조사포닌, 및 프로폴리스를 유효성분으로 포함하는 조성물을 피부에 처리하는 단계를 포함하는, 피부 보습, 항염 또는 피부진정, 또는 피부 미백 방법을 제공한다.In another aspect, cannabigerol (Cannabigerol); and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides a skin moisturizing, anti-inflammatory or skin soothing, or skin whitening method comprising the step of treating the skin with a composition comprising ginseng saponin, and propolis as an active ingredient.
다른 양태로서, 칸나비게롤(Cannabigerol); 및 아이소푸레골(isopulegol), 인삼 추출물, 병풀 추출물, 나이아신아마이드(niacinamide), 히알루론산(hyaluronic Acid), 비타민 C (vitamin C), 판테놀 (panthenol), 아데노신 (adenosine), 세드롤 (cedrol), 인삼조사포닌, 및 프로폴리스를 유효성분으로 포함하는 조성물을 대상체에 투여하는 단계를 포함하는, 피부 보습, 항염 또는 피부진정, 또는 피부 미백 방법을 제공한다.In another aspect, cannabigerol (Cannabigerol); and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides a skin moisturizing, anti-inflammatory or skin soothing, or skin whitening method comprising administering to a subject a composition comprising ginseng saponin, and propolis as an active ingredient.
다른 양태로서, 피부 보습, 항염 또는 피부진정, 또는 피부 미백용 화장료; 또는 의약외품;을 제조하기 위한 칸나비게롤(Cannabigerol); 및 아이소푸레골(isopulegol), 인삼 추출물, 병풀 추출물, 나이아신아마이드(niacinamide), 히알루론산(hyaluronic Acid), 비타민 C (vitamin C), 판테놀 (panthenol), 아데노신 (adenosine), 세드롤 (cedrol), 인삼조사포닌, 및 프로폴리스를 유효성분으로 포함하는 조성물의 용도를 제공한다.In another aspect, a cosmetic for skin moisturizing, anti-inflammatory or skin soothing, or skin whitening; Or quasi-drugs; Cannabigerol for manufacturing; and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides the use of a composition comprising ginseng saponin, and propolis as an active ingredient.
상기 유효 성분들은(칸나비게롤(Cannabigerol), 아이소푸레골(isopulegol), 인삼 추출물, 병풀 추출물, 나이아신아마이드(niacinamide), 히알루론산(hyaluronic Acid), 비타민 C (vitamin C), 판테놀 (panthenol), 아데노신 (adenosine), 세드롤 (cedrol), 인삼조사포닌, 및 프로폴리스) 상기 유효 성분의 법적으로 허용된 시판품 또는 상용 성분들이 사용될 수 있다.The active ingredients (Cannabigerol, isopulegol, ginseng extract, Centella asiatica extract, niacinamide, hyaluronic acid, vitamin C (vitamin C), panthenol (panthenol), Adenosine (adenosine), cedrol (cedrol), ginseng saponin, and propolis) Legally permitted commercial products or commercial ingredients of the active ingredient may be used.
본 발명의 "추출물"은 상기 식물 소재의 추출처리에 의하여 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다. 구체적으로 본 발명의 상기 추출물은 추출 후 건조 분말 형태로 제조되어 사용될 수 있다.The "extract" of the present invention is an extract obtained by the extraction treatment of the plant material, a diluted or concentrated liquid of the extract, a dried product obtained by drying the extract, a prepared or purified product of the extract, or a mixture thereof, such as the extract itself and extracts of all formulations that can be formed using the extract. Specifically, the extract of the present invention may be prepared and used in the form of a dry powder after extraction.
상기 인삼 또는 병풀 추출물의 제조에는 인삼 또는 병풀의 전초, 잎, 뿌리, 열매, 줄기 등 인삼 또는 병풀의 어느 부위를 사용하여도 무방하다.For the preparation of the ginseng or Centella asiatica extract, any part of ginseng or Centella asiatica, such as an outpost, leaf, root, fruit, stem, etc. of ginseng or Centella asiatica may be used.
본 발명의 "인삼조사포닌"은 인삼 추출물내에 존재하는 정제되기 전의 사포닌이며, 인삼 내에 포함되어 있는 사포닌, 사포닌으로 표시되는 물질, 사포닌으로 변화될 물질 또는 사포닌으로 추정되는 물질 모두를 말한다. 인삼에 포함된 사포닌은 파낙사디올계사포닌(Ra1, G- Ra2, G- Ra3, G- Rb1, G- Rb2, Rb3, G- Re, G- Rd, G- Rs1, G-Rs2, Rg3(20 S), G- Rg3(20 R), G- Rh2, G- Rs3, Rs4, G- Rg5, G- F4,Q - R1, N- R4, Rg6 등) 파낙사트리올계사포닌(Re, Rf, Rg1, Rg2(20 S), Rg2(20 R), Rh1(20 S), Rh2(20 R), 20- glc- Rf, N- R1, Rh4, Rf2 등), 올레인계사포닌(G-R등) 등이 있을 수 있다.The "ginseng saponin" of the present invention is a saponin present in the ginseng extract before purification, and refers to all of the saponin contained in ginseng, a substance represented by saponin, a substance to be changed to saponin, or a substance presumed to be saponin. The saponins contained in ginseng are panaxadiol-based saponins (Ra1, G-Ra2, G-Ra3, G-Rb1, G-Rb2, Rb3, G-Re, G-Rd, G-Rs1, G-Rs2, Rg3 ( 20 S), G-Rg3(20R), G-Rh2, G-Rs3, Rs4, G-Rg5, G-F4,Q-R1, N-R4, Rg6, etc.) Panaxatriol-based saponins (Re, Rf , Rg1, Rg2(20 S), Rg2(20 R), Rh1(20 S), Rh2(20 R), 20-glc-Rf, N-R1, Rh4, Rf2, etc.), oleic saponins (G-R, etc.) etc. may exist.
본 발명의 인삼조사포닌은 상기 언급된 또는 언급되지 않은 여러 종류의 인삼사포닌의 혼합물일 수 있고, 단일 종류의 인삼사포닌일 수도 있으며, 이와 대등한 효과를 나타내는 진세노사이드, 슈도진세노사이드 또는 그 외의 인삼사포닌 일수도 있다.The ginseng saponin of the present invention may be a mixture of several types of ginseng saponins mentioned above or not mentioned, or may be a single type of ginseng saponin, and ginsenoside, pseudoginsenoside, or its It may be other ginseng saponins.
상기 조성물은 화장료 또는 의약외품일 수 있다.The composition may be a cosmetic or quasi-drug.
상기 화장료는 화장수, 에센스, 로션, 크림, 팩, 젤, 파우더, 파운데이션, 밤(balm), 연고, 세정제, 헤어샴푸, 헤어토닉, 헤어린스, 헤어로션, 모발 영양화장수, 헤어트리트먼트, 헤어에센스, 헤어팩, 헤어리퀴드, 비에어로졸 무스, 비에어로졸 스프레이, 에어로졸 무스 또는 에어로졸 스프레이의 제형일 수 있으나 이에 제한되는 것은 아니다.The cosmetics include lotion, essence, lotion, cream, pack, gel, powder, foundation, balm, ointment, detergent, hair shampoo, hair tonic, hair conditioner, hair lotion, hair nourishing lotion, hair treatment, hair essence , hair pack, hair liquid, non-aerosol mousse, non-aerosol spray, aerosol mousse or aerosol spray formulation, but is not limited thereto.
본 발명의 "피부 보습"이란 피부에 수분감을 증가시켜주고, 수분 손실을 억제하여 촉촉한 상태를 유지시키는 것을 의미한다. 본 발명의 실시예에서는 HAS-2(Hyaluronan Synthase 2) 또는 AQP3(Aquaporin 3)의 발현 증가로 피부 보습 효과를 확인하였다."Moisturizing skin" of the present invention means to increase the feeling of moisture in the skin and to maintain a moist state by suppressing moisture loss. In the example of the present invention, the skin moisturizing effect was confirmed by increasing the expression of HAS-2 (Hyaluronan Synthase 2) or AQP3 (Aquaporin 3).
상기 조성물은 HAS-2 또는 AQP3의 발현 증가 효과를 가질 수 있다.The composition may have an effect of increasing the expression of HAS-2 or AQP3.
본 발명의 "항염"이란 염증을 억제하는 것을 말하며, 상기 염증은 어떤 자극에 대한 생체조직의 방어반응의 하나로, 조직 변질, 순환 장애와 삼출, 조직 증식의 세가지를 병발하는 복잡한 병변을 말한다. 보다 구체적으로 염증은 선천성 면역의 일부이며 다른 동물에서처럼 인간의 선천성 면역은 병원체에 특이적으로 존재하는 세포 표면의 패턴을 인식한다. 식세포는 그런 표면을 가진 세포를 비자기로 인식하고 병원체를 공격한다. 만일 병원균이 신체의 물리적 장벽을 깨고 들어온다면 염증반응이 일어난다. 염증반응은 상처부위에 침입한 미생물들에 대한 적대 환경을 만드는 비특이적인 방어작용이다. 염증반응에서, 상처가 나거나 외부 감염체가 체내로 들어왔을 때, 초기단계 면역반응을 맡고 있는 백혈구들이 몰려들어 사이토카인을 발현한다. 따라서 세포 내 사이토카인의 발현양이 염증반응 활성화의 지표가 된다. 염증과 관련된 피부질환의 예로는 아토피 피부염, 건선, 방사선, 화학물질, 화상 등에 의해 촉발되는 홍반성 질환, 산 화상, 수포성 피부병, 태선 모양 종류 질환, 알레르기에 기한 가려움증, 지루성 습진, 장미 여드름, 심상성 천포창, 다형 삼출성 홍반, 결절 홍반, 귀두염, 음문염, 원형 탈모증과 같은 염증성 모발 손실, 피부 T-세포 림프종 등이 있으나 이에 제한되는 것은 아니다. 특히 본 발명의 항염 효과를 통해서 예를 들어, 여드름과 같은 피부 트러블 개선 효과를 가질 수 있다. 본 발명의 실시예에서는 NO의 생성 억제로 항염 효과를 확인하였다.The term "anti-inflammatory" of the present invention refers to inhibiting inflammation, and the inflammation is one of the defense responses of a living tissue to a certain stimulus, and refers to a complex lesion that combines three types: tissue deterioration, circulatory disorder and exudation, and tissue proliferation. More specifically, inflammation is part of innate immunity, and as in other animals, human innate immunity recognizes patterns on the surface of cells that are specific to pathogens. Phagocytes recognize cells with such a surface as non-self and attack pathogens. If pathogens break through the body's physical barriers, an inflammatory response occurs. The inflammatory response is a non-specific defense action that creates a hostile environment for microorganisms that invade the wound site. In the inflammatory response, when there is a wound or an external infectious agent enters the body, the white blood cells responsible for the early stage immune response flock and express cytokines. Therefore, the expression level of intracellular cytokines is an indicator of inflammatory response activation. Examples of skin diseases associated with inflammation include atopic dermatitis, psoriasis, erythematous diseases triggered by radiation, chemicals, burns, etc., acid burns, bullous dermatosis, lichenoid type disease, itching due to allergy, seborrheic eczema, acne on roses, pemphigus vulgaris, erythema multiforme, erythema nodosum, balanitis, vulvitis, inflammatory hair loss such as alopecia areata, cutaneous T-cell lymphoma, and the like. In particular, through the anti-inflammatory effect of the present invention, for example, it may have an effect of improving skin troubles such as acne. In the example of the present invention, the anti-inflammatory effect was confirmed by inhibiting the production of NO.
본 발명의 "피부 진정"이란 염증, 또는 염증에 의해 야기되는 소양감, 발적, 통증, 작열감 또는 종창 등을 완화시키거나 감소시키는 것을 의미한다. 본 발명에서, 상기 피부 진정은 염증 감소 또는 억제에 의한 피부 진정 효과를 의미할 수 있다.As used herein, “skin soothing” means alleviating or reducing inflammation, or itching, redness, pain, burning, or swelling caused by inflammation. In the present invention, the skin soothing may mean a skin soothing effect by reducing or inhibiting inflammation.
상기 조성물은 NO의 생성 억제 효과를 가질 수 있다.The composition may have an effect of inhibiting the production of NO.
본 발명의 "미백" 이란 멜라닌 색소의 합성을 저해하여 피부 톤을 밝게 할 뿐만 아니라, 멜라닌의 피부 침착(과색소 침착증)을 억제하거나 방지, 자외선, 호르몬 또는 유전에 기인한 기미, 주근깨를 완화 또는 개선하는 모든 작용을 의미한다. 본 발명의 실시예에서는 타이로시네이즈(Tyrosinase) 활성 억제 효과를 확인하였다."Whitening" of the present invention means not only to brighten skin tone by inhibiting the synthesis of melanin, but also to inhibit or prevent melanin deposition (hyperpigmentation), to relieve or to relieve freckles caused by UV rays, hormones, or heredity. It means any action that improves. In the example of the present invention, the inhibitory effect of tyrosinase activity was confirmed.
상기 조성물은 타이로시네이즈(Tyrosinase) 활성 억제 효과를 가질 수 있다.The composition may have a tyrosinase activity inhibitory effect.
본 발명의 "화장료 조성물"은 일반적인 유화 제형 및 가용화 제형의 형태일 수 있다. 예컨대, 유연 화장수 또는 영양 화장수 등과 같은 화장수, 훼이셜 로션, 바디로션 등과 같은 유액, 영양 크림, 수분 크림, 아이 크림 등과 같은 크림, 에센스, 화장연고, 밤(balm), 스프레이, 젤, 팩, 선 스크린, 메이크업 베이스, 액체 타입, 고체 타입 또는 스프레이 타입 등의 파운데이션, 파우더, 클렌징 크림, 클렌징 로션, 클렌징 오일과 같은 메이크업 제거제, 클렌징 폼, 비누, 바디 워시 등과 같은 세정제 등의 제형을 가질 수 있으나 이에 제한되는 것은 아니다. The "cosmetics composition" of the present invention may be in the form of general emulsified formulations and solubilized formulations. For example, lotions such as flexible lotions or nourishing lotions, emulsions such as facial lotions and body lotions, creams such as nourishing creams, moisture creams, and eye creams, essences, cosmetic ointments, balms, sprays, gels, packs, sunscreens , makeup base, liquid type, solid type or spray type foundation, powder, cleansing cream, cleansing lotion, makeup remover such as cleansing oil, cleansing agent such as cleansing foam, soap, body wash, etc., but is limited thereto it's not going to be
또한, 상기 화장품은 본 발명의 조성물에 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다.In addition, in the composition of the present invention, the cosmetic includes a fatty substance, an organic solvent, a solubilizer, a thickening agent and a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, Ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any conventionally used in cosmetics It may contain adjuvants commonly used in the field of cosmetology such as other ingredients of
상기 화장료 제형은 유효성분이 단기간 내에 피부에 머무르게 되는 메이크업 제거제, 세정제 등과 같은 워시-오프(wash-off) 타입의 화장품의 경우에는 비교적 높은 농도의 상기 본 발명의 조성물을 포함할 수 있을 것이다. 반면, 유효성분이 장기간 동안 피부에 머무르게 되는 화장수, 유액, 크림, 에센스 등의 리브-온(leave-on) 타입의 화장품의 경우에는 워시-오프 타입의 화장품에 비해 낮은 농도의 상기 본 발명의 조성물을 포함해도 무방할 것이다. 이에 제한되는 것은 아니나, 본 발명의 한 구체예에서, 상기 조성물은 상기 본 발명의 조성물을 전체 조성물 중량에 대하여 0.000001 중량% 내지 10 중량%(바람직하게는 0.000001 중량% 내지 1 중량%)로 포함할 수 있다. 본 발명의 조성물이 상기 본 발명의 조성물을 0.000001 중량% 미만으로 포함할 경우에는 충분한 보습, 항염 또는 피부 진정, 미백 효과를 기대할 수 없고, 10 중량%를 초과하여 포함할 경우에는 알러지 등 원치 않는 반응이 발생하거나 피부 안전성에 문제가 있을 수 있으므로 이를 방지하기 위한 것이다.The cosmetic formulation may include a relatively high concentration of the composition of the present invention in the case of a wash-off type cosmetic such as a makeup remover or a detergent in which the active ingredient stays on the skin within a short period of time. On the other hand, in the case of leave-on type cosmetics such as lotions, emulsions, creams, and essences, in which the active ingredients stay on the skin for a long time, the composition of the present invention at a lower concentration than the wash-off type cosmetics. would be free to include. Although not limited thereto, in one embodiment of the present invention, the composition comprises 0.000001% to 10% by weight (preferably 0.000001% to 1% by weight) of the composition of the present invention based on the total weight of the composition. can When the composition of the present invention contains less than 0.000001% by weight of the composition of the present invention, sufficient moisturizing, anti-inflammatory or skin soothing and whitening effects cannot be expected, and when it contains more than 10% by weight, unwanted reactions such as allergies This is to prevent this from occurring or there may be problems with skin safety.
본 발명의 "의약외품 조성물"은 사람이나 동물의 질병을 진단, 치료, 경감, 처치 또는 예방할 목적으로 사용되나, 의약품 보다 인체에 미치는 작용이 경미한 물품을 의미하고, 물품 중 기구, 기계 또는 장치가 아닌 것 및 사람이나 동물의 구조와 기능에 약리학적 영향을 줄 목적으로 사용하는 물품 중 기구, 기계 또는 장치가 아닌 것을 제외한 물품용 조성물을 의미한다. 약사법에 따른 의약품의 용도로 사용되는 물품을 제외하며, 일 구체예로 피부 외용제, 개인위생용품 또는 내복용 제제를 포함할 수 있으나 이에 제한되는 것이 아니며, 의약외품의 제제화 방법, 용량, 이용방법, 구성성분 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있다. The "quasi-drug composition" of the present invention refers to an article that is used for the purpose of diagnosing, treating, alleviating, treating or preventing diseases of humans or animals, but has a milder effect on the human body than pharmaceuticals, and is not an instrument, machine or device among articles It means a composition for articles other than instruments, machines, or devices among articles used for the purpose of pharmacologically affecting the structure and function of humans or animals. Except for articles used for pharmaceutical purposes according to the Pharmaceutical Affairs Act, one embodiment may include, but is not limited to, external preparations for skin, personal care products, or preparations for internal use. Components and the like may be appropriately selected from conventional techniques known in the art.
본 발명에 따른 조성물에 포함되는 상기 언급된 성분들 각각은 바람직하게는 각 국 정부에 의해 규정된 규범에 명시된 최대 사용량을 초과하지 않는 범위 내에서 본 발명의 조성물에 포함될 수 있다. 예를 들어, 화장료 조성물을 제공하는 경우 각 국 정부에서 규정하는 화장품 안전에 관한 법률 또는 중국 정부에서 규정하는 《화장품 안전 기술 사양》 에 명시된 최대 사용량을 초과하지 않는 범위 내에서 본 발명의 화장료 조성물에 포함될 수 있다. Each of the above-mentioned components included in the composition according to the present invention may be included in the composition of the present invention, preferably within a range not exceeding the maximum amount specified in the norms stipulated by the respective national governments. For example, in the case of providing a cosmetic composition, the cosmetic composition of the present invention may be added to the cosmetic composition of the present invention within a range that does not exceed the maximum amount specified in the Cosmetic Safety Act stipulated by each country or the “Cosmeceutical Safety Technical Specification” stipulated by the Chinese government. may be included.
이하, 본 발명을 하기 실험예에 의해 상세히 설명한다. 단, 하기 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실험예에 의해 제한되는 것은 아니다. 또한, 이들 실험예는 본 발명에 대한 이해를 돕기 위한 목적일 뿐이므로, 어떤 의미로든 본 발명의 범위가 이들에 의해 제한되는 것은 아니다.Hereinafter, the present invention will be described in detail by the following experimental examples. However, the following experimental examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following experimental examples. In addition, since these experimental examples are only for the purpose of helping the understanding of the present invention, the scope of the present invention is not limited thereto in any sense.
실험예 1: 실험 시료 제조Experimental Example 1: Preparation of test samples
실험에 앞서, 하기와 같이 추출물을 제조하였다.Prior to the experiment, extracts were prepared as follows.
인삼 추출물 제조Ginseng Extract Manufacturing
인삼(Panax ginseng) 뿌리를 질량의 30배에 해당하는 70% 에탄올 수용액을 가하여 상온에서 3일간 추출한 후 감압 여과하였다. 여과한 추출물은 rotary evaporator(Buchi, Switzerland)로 농축, 건조하여 추출물을 제조하였다.Ginseng (Panax ginseng) roots were extracted with 70% ethanol aqueous solution corresponding to 30 times the mass at room temperature for 3 days, and then filtered under reduced pressure. The filtered extract was concentrated and dried with a rotary evaporator (Buchi, Switzerland) to prepare an extract.
병풀 추출물 제조Centella asiatica extract preparation
병풀(Centella asiatica) 잎을 질량의 30배에 해당하는 70% 에탄올 수용액을 가하여 상온에서 3일간 추출한 후 감압 여과하였다. 여과한 추출물은 rotary evaporator(Buchi, Switzerland)로 농축, 건조하여 추출물을 제조하였다.Centella asiatica leaves were extracted with 70% ethanol aqueous solution corresponding to 30 times the mass at room temperature for 3 days, and then filtered under reduced pressure. The filtered extract was concentrated and dried with a rotary evaporator (Buchi, Switzerland) to prepare an extract.
인삼조사포닌 제조Manufacture of ginseng saponin
제조한 인삼 추출물을 물과 수포화부탄올을 동량 섞은 용매로 3회 반복 추출하고 수포화부탄올 층을 합하여 rotary evaporator(Buchi, Switzerland)로 감압농축하였다.The prepared ginseng extract was extracted three times with a solvent in which equal amounts of water and saturated butanol were mixed, and the saturated butanol layers were combined and concentrated under reduced pressure using a rotary evaporator (Buchi, Switzerland).
상기 추출물 외의 시료는 하기와 같다.Samples other than the extract are as follows.
시료 번호sample number | 조성물composition |
비교예 1Comparative Example 1 | 무첨가 대조군no-addition control |
비교예 2Comparative Example 2 | 양성 대조군(각 효능 평가 실험 참조)Positive control (see each efficacy evaluation trial) |
실시예 1Example 1 | 칸나비게롤 (Cannabigerol, CBG)Cannabigerol (CBG) |
실시예 2Example 2 | 이소푸레골isopuregol |
실시예 3Example 3 | 인삼 추출물Ginseng Extract |
실시예 4Example 4 | 병풀 추출물Centella asiatica extract |
실시예 5Example 5 | 나이아신아마이드Niacinamide |
실시예 6Example 6 | 히알루론산hyaluronic acid |
실시예 7Example 7 | 비타민 cvitamin c |
실시예 8Example 8 | 판테놀panthenol |
실시예 9Example 9 | 아데노신adenosine |
실시예 10Example 10 | 세드롤cedrol |
실시예 11Example 11 | 인삼조사포닌ginseng saponin |
실시예 12Example 12 | 프로폴리스propolis |
하기 실험예 1-1 내지 1-4의 실험 방법에 따라 시료의 각 성분의 농도가 조절되었다.Concentrations of each component of the sample were adjusted according to the experimental methods of Experimental Examples 1-1 to 1-4 below.
<실험예 1-1> 보습 효능 평가<Experimental Example 1-1> Moisturizing efficacy evaluation
보습 효과를 검증하기 위하여 섬유아세포(fibroblast)를 이용하여 HAS-2, AQP3의 발현 증가 정도를 확인하였다. 섬유아세포는 10% FBS (Fetal Bovine Serum)가 첨가된 DMEM(Dulbecco's Modified Eagle's Medium, Gibco)을 기본 배지로 하여 2~5 x 104 cells/㎖ 농도로 seeding하고 배양하였다. 배양된 세포를 10% FBS와 칼슘 이온이 포함되지 않은 DMEM배지로 옮긴 후, 실시예 및 비교예를 아래 표 2에 해당하는 농도로 단독 및 조합 처리하여 24시간 동안 배양하였다. 24시간 경과 후 세포를 회수하여 인산완충생리식염수(Phosphate-Buffered Saline, PBS)로 세척하고, RNeasy mini kit (Qiagen, 카탈로그 넘버 74104)를 이용하여 전체 RNA를 추출하였다. RNA를 cDNA Synthesis Kit (PhileKorea) 이용하여 역전사반응을 수행하였다. 합성된 cDNA는 정량 후 물로 희석하여 모든 반응에 동일 양을 사용하였다. TaqMan® Universal Master Mix II(Thermo Fisher, 카탈로그 넘버 4440043)와 TaqMan® GeneExpression Assays (Thermo Fisher, 카탈로그 넘버 4331348), HAS2 프라이머(5'-CCCAAAATGTGAAGCTTGGT -3'), AQP3 프라이머(5'-AGACAGCCCCTTCAGGATTT-3')를 사용하였다. StepOnePlus® Realtime PCR System (Applied Biosystems, 카탈로그 넘버 4376600)를 이용하여 실시간 중합 효소 연쇄 반응(quantitative real time PCR)을 수행하였다. 실험 결과는 하우스키핑 유전자(housekeeping gene) Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 5'-TGCACCACCAACTGCTTAGC-3')를 기준으로 ΔΔCt 방법으로 계산하여 나타내었다. 양성 대조군(비교예 2)으로는 all-trans-Retinoic acid 100 nM를 사용하였다. 각 시료의 HAS2, AQP3 유전 자의 발현 정도는 추출물을 첨가하지 않은 비교예 1의 mRNA 발현량을 100%로 기준하여 수치화하였으며, 그 결과를 하기 표 2에 나타내었다. 하기 표 2내의 실시예 2, 5 내지 10 의 "실시예 1과의 조합"은 실시예 1 0.0001%와 실시예 2, 5 내지 10 0.0009%를 포함하여 0.001%의 총 시료 농도로 처리된 것이며,To verify the moisturizing effect, the expression level of HAS-2 and AQP3 increased using fibroblasts was confirmed. Fibroblasts were seeded and cultured at a concentration of 2-5 x 10 4 cells/ml using DMEM (Dulbecco's Modified Eagle's Medium, Gibco) supplemented with 10% FBS (Fetal Bovine Serum) as a basal medium. After the cultured cells were transferred to DMEM medium not containing 10% FBS and calcium ions, Examples and Comparative Examples were treated alone or in combination at concentrations corresponding to Table 2 below and cultured for 24 hours. After 24 hours, the cells were recovered, washed with phosphate-buffered saline (PBS), and total RNA was extracted using an RNeasy mini kit (Qiagen, catalog number 74104). RNA was subjected to reverse transcription using cDNA Synthesis Kit (PhileKorea). The synthesized cDNA was quantified, diluted with water, and the same amount was used for all reactions. TaqMan® Universal Master Mix II (Thermo Fisher, catalog number 4440043) with TaqMan® GeneExpression Assays (Thermo Fisher, catalog number 4331348), HAS2 primer (5'-CCCAAAATGTGAAGCTTGGT -3'), AQP3 primer (5'-AGACAGCCCCTTCAGGATTT-3' ) was used. Quantitative real time PCR was performed using the StepOnePlus® Realtime PCR System (Applied Biosystems, catalog number 4376600). The experimental results were calculated using the ΔΔCt method based on the housekeeping gene Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 5'-TGCACCACCAACTGCTTAGC-3'). 100 nM of all-trans-Retinoic acid was used as a positive control (Comparative Example 2). The expression level of the HAS2 and AQP3 genes of each sample was quantified based on 100% of the mRNA expression level of Comparative Example 1 without the addition of the extract, and the results are shown in Table 2 below. “Combination with Example 1” of Examples 2, 5 to 10 in Table 2 below is treated with a total sample concentration of 0.001%, including 0.0001% of Example 1 and 0.0009% of Examples 2, 5-10,
실시예 3, 4, 11 및 12의 "실시예 1과의 조합"은 실시예 1 0.0001%와 실시예 3, 4, 11 및 12 0.0099%를 포함하여 0.01%의 총 시료 농도로 처리된 것이다."Combination with Example 1" of Examples 3, 4, 11 and 12 was treated with a total sample concentration of 0.01%, including 0.0001% of Example 1 and 0.0099% of Examples 3, 4, 11 and 12.
시료 번호sample number | 시료 농도sample concentration | HAS2 mRNA 농도 증가율 (%)HAS2 mRNA concentration increase rate (%) | AQP3 mRNA 농도 증가율 (%)AQP3 mRNA concentration increase rate (%) | ||
각 시료 단독 사용Use of each sample alone | 실시예 1과 조합Combination with Example 1 | 각 시료 단독 사용Use of each sample alone | 실시예 1과 조합Combination with Example 1 | ||
비교예 1Comparative Example 1 | 0.000.00 | 00 | |||
비교예 2Comparative Example 2 | 35.5935.59 | 21.3221.32 | |||
실시예 1Example 1 | 0.0001%0.0001% | 8.548.54 | 7.667.66 | ||
실시예 2Example 2 | 0.001%0.001% | 2.252.25 | 29.8129.81 | 11.4011.40 | 25.1425.14 |
실시예 3Example 3 | 0.01%0.01% | 16.7316.73 | 43.1543.15 | 4.494.49 | 19.0619.06 |
실시예 4Example 4 | 0.01%0.01% | 15.0015.00 | 32.9532.95 | 2.512.51 | 20.9320.93 |
실시예 5Example 5 | 0.001%0.001% | 6.726.72 | 18.1018.10 | 8.978.97 | 18.1418.14 |
실시예 6Example 6 | 0.001%0.001% | 6.416.41 | 33.7933.79 | 3.783.78 | 12.7612.76 |
실시예 7Example 7 | 0.001%0.001% | 18.3218.32 | 46.3146.31 | 7.887.88 | 20.2820.28 |
실시예 8Example 8 | 0.001%0.001% | 3.173.17 | 16.9516.95 | 2.482.48 | 20.5320.53 |
실시예 9Example 9 | 0.001%0.001% | 2.512.51 | 31.2431.24 | 6.236.23 | 22.2522.25 |
실시예 10Example 10 | 0.001%0.001% | 8.068.06 | 22.6722.67 | 0.980.98 | 16.5916.59 |
실시예 11Example 11 | 0.01%0.01% | 5.835.83 | 44.2544.25 | 4.264.26 | 20.7220.72 |
실시예 12Example 12 | 0.01%0.01% | 6.096.09 | 35.5435.54 | 4.904.90 | 23.9423.94 |
상기 표 2와 같이, 실시예 1과 실시예 2 내지 12의 조합을 통해 비교예 1 대비 HAS2 mRNA와 AOP3 mRNA 농도가 증가함을 확인하였고, 단독 대비 조합을 통한 상승 효과를 확인하였다.As shown in Table 2, it was confirmed that the concentrations of HAS2 mRNA and AOP3 mRNA increased compared to Comparative Example 1 through the combination of Example 1 and Examples 2 to 12, and the synergistic effect was confirmed through the combination compared to the single.
<실험예 1-2> 항염 효능 평가<Experimental Example 1-2> Anti-inflammatory efficacy evaluation
피부 진정 및 염증 개선 효과를 검증하기 위하여, NO 생성 억제 효과를 mouse macrophage cell line인 Raw 264.7 세포(ATCC, 카탈로그 넘버 CRL-2788)를 이용하여 측정하였다. DMEM 에 10% FBS 를 첨가하여 성장 배지로 이용하였으며 Raw264.7 세포를 1~2 x 105 cells/㎖ 농도로 seeding 하고 5% CO2 incubator에서 하루 동안 배양하였다. 배지를 제거하고 무혈청배지로 12시간 starvation 시킨 후, 실시예 및 비교예를 아래 표 3에 해당하는 농도로 단독 및 조합 처리하여 30 분 동안 전처리 하였다. 이후, 500 ng/ml의 LPS(Lipopolysaccharides, SIGMA, 카탈로그 넘버 L43901)를 처리하고 18 시간 동안 배양하였다. 배양 후 상층액을 취해 96-well tissue culture plate에 옮기고, GREISS reagent(SIGMA, 카탈로그 넘버 G4410)를 가해 상온에서 15분간 반응시킨 후 ELISA reader를 이용하여 540 nm에서 흡광도를 측정하였다. 양성 대조군(비교예 2)으로는 L-NMMA 100 μM을 사용하였다. 이후, NO 정량 키트를 이용하여 NO 생성 억제능을 하기 식과 같이 평가하였으며, 그 결과는 아래 표 3에 나타내었다. 하기 표 3내의 실시예 2, 5 내지 10 의 "실시예 1과의 조합"은 실시예 1 0.0001%와 실시예 2, 5 내지 10 0.0009%를 포함하여 0.001%의 총 시료 농도로 처리된 것이며,In order to verify the skin soothing and inflammation improvement effect, the NO production inhibitory effect was measured using a mouse macrophage cell line, Raw 264.7 cells (ATCC, catalog number CRL-2788). 10% FBS was added to DMEM and used as a growth medium. Raw264.7 cells were seeded at a concentration of 1 to 2 x 10 5 cells/ml and cultured in a 5% CO 2 incubator for one day. After removing the medium and starvation with a serum-free medium for 12 hours, Examples and Comparative Examples were treated alone or in combination at the concentrations corresponding to Table 3 below and pre-treated for 30 minutes. Then, 500 ng/ml of LPS (Lipopolysaccharides, SIGMA, catalog number L43901) was treated and cultured for 18 hours. After incubation, the supernatant was taken and transferred to a 96-well tissue culture plate, GREISS reagent (SIGMA, catalog number G4410) was added and reacted at room temperature for 15 minutes, and then absorbance was measured at 540 nm using an ELISA reader. As a positive control (Comparative Example 2), 100 μM of L-NMMA was used. Then, the NO production inhibitory ability was evaluated using the NO quantification kit as follows, and the results are shown in Table 3 below. “Combination with Example 1” of Examples 2, 5 to 10 in Table 3 below is treated with a total sample concentration of 0.001%, including 0.0001% of Example 1 and 0.0009% of Examples 2, 5-10,
실시예 3, 4, 11 및 12의 "실시예 1과의 조합"은 실시예 1 0.0001%와 실시예 3, 4, 11 및 12 0.0099%를 포함하여 0.01%의 총 시료 농도로 처리된 것이다."Combination with Example 1" of Examples 3, 4, 11 and 12 was treated with a total sample concentration of 0.01%, including 0.0001% of Example 1 and 0.0099% of Examples 3, 4, 11 and 12.
- NO 생성 억제능(%)={1-(시료 첨가시 NO 생성량/시료 무첨가시 NO 생성량)}x100- NO production inhibition ability (%) = {1-(NO production amount when sample is added / NO production amount when sample is not added)}x100
시료 번호sample number | 시료 농도sample concentration | NO 생성 억제능(%)NO production inhibition ability (%) | |
각 시료 단독 사용Use of each sample alone | 실시예 1과 조합Combination with Example 1 | ||
비교예 1Comparative Example 1 | 0.000.00 | ||
비교예 2Comparative Example 2 | 53.0253.02 | ||
실시예 1Example 1 | 0.0001%0.0001% | 26.2126.21 | |
실시예 2Example 2 | 0.001%0.001% | 13.5013.50 | 59.0459.04 |
실시예 3Example 3 | 0.01%0.01% | 27.1827.18 | 62.3862.38 |
실시예 4Example 4 | 0.01%0.01% | 27.5327.53 | 57.7357.73 |
실시예 5Example 5 | 0.001%0.001% | 9.849.84 | 53.6753.67 |
실시예 6Example 6 | 0.001%0.001% | 24.0924.09 | 60.7460.74 |
실시예 7Example 7 | 0.001%0.001% | 37.8137.81 | 66.9066.90 |
실시예 8Example 8 | 0.001%0.001% | 21.4221.42 | 57.9757.97 |
실시예 9Example 9 | 0.001%0.001% | 24.1224.12 | 60.9160.91 |
실시예 10Example 10 | 0.001%0.001% | 12.4712.47 | 52.7252.72 |
실시예 11Example 11 | 0.01%0.01% | 19.4219.42 | 60.7060.70 |
실시예 12Example 12 | 0.01%0.01% | 25.6325.63 | 57.8057.80 |
상기 표 3과 같이, 실시예 1과 실시예 2 내지 12의 조합을 통해 비교예 1 대비 NO 생성 억제능이 증가함을 확인하였고, 단독 대비 조합을 통한 상승 효과를 확인하였다.As shown in Table 3, it was confirmed that the NO production inhibitory ability was increased compared to Comparative Example 1 through the combination of Example 1 and Examples 2 to 12, and the synergistic effect was confirmed through the combination compared to the single one.
<실험예 1-3> 피부 미백 효능 평가 (Melanin test)<Experimental Example 1-3> Skin whitening efficacy evaluation (Melanin test)
미백 효과를 검증하기 위해, 멜라닌 세포(Melanocyte) 내에 타이로시네이즈 활성(Tyrosinase activity) 정도를 측정하여 비교하였다. MNT-1 멜라노마 세포(ATCC, 카탈로그 넘버 CRL-3450)를 10% FBS가 포함된 DMEM 배지에 1~2 x 105 cells/㎖의 농도로 seeding하고 24시간 배양하였다. 실시예 및 비교예를 아래 표 4에 해당하는 농도로 배양된 멜라닌 세포에 단독 및 조합 처리하여 72시간 배양한 후, 세포를 회수하였다. 13,000 rpm으로 1분간 원심 분리하고 상층액을 제거한 후, pellet에 0.5% triton X-100 용액 300 μl를 첨가하여 세포를 lysis 하였다. 이를 다시 13,000 rpm으로 3분간 원심 분리하고 pellet과 상층액을 따로 회수하였다. 회수한 cell lysis 상층액 100 μl를 취하고 여기에 1 mM L-DOPA(SIGMA) 용액을 첨가한 후 37℃에서 1시간 반응시켰다. 반응액은 ELISA reader를 이용하여 450nm 흡광도를 측정하였다. 양성 대조군(비교예 2)으로는 알부틴(arbutin) 200 μl/mL를 사용하였다. 하기 표 4내의 실시예 2, 5 내지 10 의 "실시예 1과의 조합"은 실시예 1 0.0001%와 실시예 2, 5 내지 10 0.0009%를 포함하여 0.001%의 총 시료 농도로 처리된 것이며,To verify the whitening effect, the degree of tyrosinase activity in melanocytes was measured and compared. MNT-1 melanoma cells (ATCC, catalog number CRL-3450) were seeded in DMEM medium containing 10% FBS at a concentration of 1 to 2 x 10 5 cells/ml and cultured for 24 hours. Examples and Comparative Examples were treated alone or in combination on melanocytes cultured at the concentration corresponding to Table 4 below and cultured for 72 hours, and then the cells were recovered. After centrifugation at 13,000 rpm for 1 minute and removing the supernatant, 300 μl of 0.5% triton X-100 solution was added to the pellet to lyse the cells. This was again centrifuged at 13,000 rpm for 3 minutes, and the pellet and the supernatant were separately recovered. Take 100 μl of the recovered cell lysis supernatant, add 1 mM L-DOPA (SIGMA) solution thereto, and react at 37° C. for 1 hour. The reaction solution was measured for absorbance at 450 nm using an ELISA reader. As a positive control (Comparative Example 2), 200 μl/mL of arbutin was used. "Combination with Example 1" of Examples 2, 5 to 10 in Table 4 below is treated with a total sample concentration of 0.001%, including 0.0001% of Example 1 and 0.0009% of Examples 2, 5-10,
실시예 3, 4, 11 및 12의 "실시예 1과의 조합"은 실시예 1 0.0001%와 실시예 3, 4, 11 및 12 0.0099%를 포함하여 0.01%의 총 시료 농도로 처리된 것이다."Combination with Example 1" of Examples 3, 4, 11 and 12 was treated with a total sample concentration of 0.01%, including 0.0001% of Example 1 and 0.0099% of Examples 3, 4, 11 and 12.
시료 번호sample number | 시료 농도sample concentration | 타이로시네이즈 활성 (%)Tyrosinase activity (%) | |
각 시료 단독 사용Use of each sample alone | 실시예 1과 조합Combination with Example 1 | ||
비교예 1Comparative Example 1 | 100100 | ||
비교예 2Comparative Example 2 | 57.9457.94 | ||
실시예 1Example 1 | 0.0001%0.0001% | 89.7589.75 | |
실시예 2Example 2 | 0.001%0.001% | 98.2398.23 | 72.7972.79 |
실시예 3Example 3 | 0.01%0.01% | 89.3489.34 | 70.1070.10 |
실시예 4Example 4 | 0.01%0.01% | 80.9380.93 | 61.2861.28 |
실시예 5Example 5 | 0.001%0.001% | 77.2577.25 | 60.9960.99 |
실시예 6Example 6 | 0.001%0.001% | 88.9888.98 | 66.9966.99 |
실시예 7Example 7 | 0.001%0.001% | 73.8473.84 | 51.7751.77 |
실시예 8Example 8 | 0.001%0.001% | 98.5998.59 | 75.4875.48 |
실시예 9Example 9 | 0.001%0.001% | 77.9177.91 | 50.0550.05 |
실시예 10Example 10 | 0.001%0.001% | 95.6895.68 | 76.7776.77 |
실시예 11Example 11 | 0.01%0.01% | 84.4284.42 | 71.3971.39 |
실시예 12Example 12 | 0.01%0.01% | 92.2692.26 | 77.4477.44 |
상기 표 4와 같이, 실시예 1과 실시예 2 내지 12의 조합을 통해 비교예 1 대비 타이로시네이즈의 활성이 억제됨을 확인하였고, 단독 대비 조합을 통한 상승 효과를 확인하였다.As shown in Table 4, it was confirmed that the activity of tyrosinase was inhibited compared to Comparative Example 1 through the combination of Example 1 and Examples 2 to 12, and the synergistic effect was confirmed through the combination compared to the single.
Claims (12)
- 칸나비게롤(Cannabigerol); 및Cannabigerol; and아이소푸레골(isopulegol), 인삼 추출물, 병풀 추출물, 나이아신아마이드(niacinamide), 히알루론산(hyaluronic Acid), 비타민 C (vitamin C), 판테놀 (panthenol), 아데노신 (adenosine), 세드롤 (cedrol), 인삼조사포닌, 및 프로폴리스로 이루어진 군으로부터 선택된 하나 또는 그 이상;을 포함하는, 피부 보습용 조성물. isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, ginseng A composition for skin moisturizing, including; one or more selected from the group consisting of saponin, and propolis.
- 제 1항에 있어서,The method of claim 1,상기 조성물은 화장료 또는 의약외품인, 피부 보습용 조성물.The composition is a cosmetic or quasi-drug, skin moisturizing composition.
- 제 2항에 있어서,3. The method of claim 2,상기 화장료는 화장수, 에센스, 로션, 크림, 팩, 젤, 파우더, 파운데이션, 밤(balm), 연고, 세정제, 헤어샴푸, 헤어토닉, 헤어린스, 헤어로션, 모발 영양화장수, 헤어트리트먼트, 헤어에센스, 헤어팩, 헤어리퀴드, 비에어로졸 무스, 비에어로졸 스프레이, 에어로졸 무스 또는 에어로졸 스프레이의 제형인, 피부 보습용 조성물.The cosmetics include lotion, essence, lotion, cream, pack, gel, powder, foundation, balm, ointment, detergent, hair shampoo, hair tonic, hair conditioner, hair lotion, hair nourishing lotion, hair treatment, hair essence , hair pack, hair liquid, non-aerosol mousse, non-aerosol spray, aerosol mousse or aerosol spray formulation, skin moisturizing composition.
- 제 1항에 있어서, The method of claim 1,상기 조성물은 HAS-2 또는 AQP3의 발현 증가 효과를 갖는, 피부 보습용 조성물.The composition has an effect of increasing the expression of HAS-2 or AQP3, a composition for skin moisturizing.
- 칸나비게롤(Cannabigerol); 및Cannabigerol; and아이소푸레골(isopulegol), 인삼 추출물, 병풀 추출물, 나이아신아마이드(niacinamide), 히알루론산(hyaluronic Acid), 비타민 C (vitamin C), 판테놀 (panthenol), 아데노신 (adenosine), 세드롤 (cedrol), 인삼조사포닌, 및 프로폴리스로 이루어진 군으로부터 선택된 하나 또는 그 이상;을 포함하는, 항염 또는 피부 진정용 조성물. isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, ginseng Josaponin, and one or more selected from the group consisting of propolis; Containing, anti-inflammatory or skin soothing composition.
- 제 5항에 있어서,6. The method of claim 5,상기 조성물은 화장료 또는 의약외품인, 항염 또는 피부 진정용 조성물.The composition is a cosmetic or quasi-drug, anti-inflammatory or skin soothing composition.
- 제 6항에 있어서,7. The method of claim 6,상기 화장료는 화장수, 에센스, 로션, 크림, 팩, 젤, 파우더, 파운데이션, 밤(balm), 연고, 세정제, 헤어샴푸, 헤어토닉, 헤어린스, 헤어로션, 모발 영양화장수, 헤어트리트먼트, 헤어에센스, 헤어팩, 헤어리퀴드, 비에어로졸 무스, 비에어로졸 스프레이, 에어로졸 무스 또는 에어로졸 스프레이의 제형인, 항염 또는 피부 진정용 조성물.The cosmetics include lotion, essence, lotion, cream, pack, gel, powder, foundation, balm, ointment, detergent, hair shampoo, hair tonic, hair rinse, hair lotion, hair nourishing lotion, hair treatment, hair essence , hair pack, hair liquid, non-aerosol mousse, non-aerosol spray, aerosol mousse or aerosol spray formulation, anti-inflammatory or skin soothing composition.
- 제 6항에 있어서, 7. The method of claim 6,상기 조성물은 NO의 생성 억제 효과를 갖는, 항염 또는 피부 진정용 조성물.The composition has a NO production inhibitory effect, anti-inflammatory or skin soothing composition.
- 칸나비게롤(Cannabigerol); 및Cannabigerol; and아이소푸레골(isopulegol), 인삼 추출물, 병풀 추출물, 나이아신아마이드(niacinamide), 히알루론산(hyaluronic Acid), 비타민 C (vitamin C), 판테놀 (panthenol), 아데노신 (adenosine), 세드롤 (cedrol), 인삼조사포닌, 및 프로폴리스로 이루어진 군으로부터 선택된 하나 또는 그 이상;을 포함하는, 미백용 조성물. isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, ginseng One or more selected from the group consisting of saponin, and propolis; Containing, a composition for whitening.
- 제 9항에 있어서,10. The method of claim 9,상기 조성물은 화장료 또는 의약외품인, 미백용 조성물.The composition is a cosmetic or quasi-drug, a composition for whitening.
- 제 10항에 있어서,11. The method of claim 10,상기 화장료는 화장수, 에센스, 로션, 크림, 팩, 젤, 파우더, 파운데이션, 밤(balm), 연고, 세정제, 헤어샴푸, 헤어토닉, 헤어린스, 헤어로션, 모발 영양화장수, 헤어트리트먼트, 헤어에센스, 헤어팩, 헤어리퀴드, 비에어로졸 무스, 비에어로졸 스프레이, 에어로졸 무스 또는 에어로졸 스프레이의 제형인, 미백용 조성물.The cosmetics include lotion, essence, lotion, cream, pack, gel, powder, foundation, balm, ointment, detergent, hair shampoo, hair tonic, hair rinse, hair lotion, hair nourishing lotion, hair treatment, hair essence , The formulation of a hair pack, hair liquid, non-aerosol mousse, non-aerosol spray, aerosol mousse or aerosol spray, the composition for whitening.
- 제 9항에 있어서, 10. The method of claim 9,상기 조성물은 타이로시네이즈(Tyrosinase) 활성 억제 효과를 갖는, 미백용 조성물.The composition has a tyrosinase (Tyrosinase) activity inhibitory effect, whitening composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0030241 | 2021-03-08 | ||
KR20210030241 | 2021-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022191551A1 true WO2022191551A1 (en) | 2022-09-15 |
Family
ID=83227945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/003210 WO2022191551A1 (en) | 2021-03-08 | 2022-03-07 | Composition comprising cannabigerol |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20220126653A (en) |
WO (1) | WO2022191551A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115778828A (en) * | 2023-02-10 | 2023-03-14 | 安婕妤化妆品科技股份有限公司 | Cosmetic composition containing fullerene |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10206888B2 (en) * | 2017-06-06 | 2019-02-19 | Cmg Partners, Inc. | Cannabis-based therapeutic product for treatment of chronic pain |
KR20190034576A (en) * | 2016-08-03 | 2019-04-02 | 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 | Cannabis composition |
US20200188325A1 (en) * | 2015-02-16 | 2020-06-18 | Axim Biotechnologies, Inc. | Cosmetic and topical compositions comprising cannabigerol |
WO2020249184A1 (en) * | 2019-06-11 | 2020-12-17 | Symrise Ag | Synthesis and purification of cannabigerol and its application |
KR20210008327A (en) * | 2018-01-13 | 2021-01-21 | 트루티바 인코포레이티드 | Anti-aging and skin tone whitening composition and method therefor |
-
2022
- 2022-03-07 KR KR1020220028843A patent/KR20220126653A/en unknown
- 2022-03-07 WO PCT/KR2022/003210 patent/WO2022191551A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200188325A1 (en) * | 2015-02-16 | 2020-06-18 | Axim Biotechnologies, Inc. | Cosmetic and topical compositions comprising cannabigerol |
KR20190034576A (en) * | 2016-08-03 | 2019-04-02 | 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 | Cannabis composition |
US10206888B2 (en) * | 2017-06-06 | 2019-02-19 | Cmg Partners, Inc. | Cannabis-based therapeutic product for treatment of chronic pain |
KR20210008327A (en) * | 2018-01-13 | 2021-01-21 | 트루티바 인코포레이티드 | Anti-aging and skin tone whitening composition and method therefor |
WO2020249184A1 (en) * | 2019-06-11 | 2020-12-17 | Symrise Ag | Synthesis and purification of cannabigerol and its application |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115778828A (en) * | 2023-02-10 | 2023-03-14 | 安婕妤化妆品科技股份有限公司 | Cosmetic composition containing fullerene |
Also Published As
Publication number | Publication date |
---|---|
KR20220126653A (en) | 2022-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2889027B1 (en) | Oral preparation, injection preparation, external skin preparation and cosmetic method for preventing or improving wrinkles | |
KR102257524B1 (en) | Cosmetic composition for improving skin condition Centella Asiatica―derived exsome having skin calming and regeneration | |
US20090028969A1 (en) | Compostion for treating skin | |
Devi et al. | Study of antioxdant, antiinflammatory and woundhealing activity of extracts of Litsea glutinosa | |
WO2011122869A2 (en) | Cosmetic composition comprising coumestrol or a bean extract containing coumestrol for skin care | |
DE102008059523A1 (en) | Cosmetic mixture containing ascorbic acid-2-glucoside and ergothioneine | |
KR101928797B1 (en) | Composition of skin external application containing compound K | |
KR102021463B1 (en) | External composition for skin containing Ginsenoside Rg3 | |
KR20130088912A (en) | Skin external composition containing tangeretin and egcg | |
WO2017043670A1 (en) | Cosmetic composition containing citron extract | |
KR101460569B1 (en) | Cosmetic composition comprising of gingenoside F2 for skin wrinkle improvement, skin whitening or anti-acne | |
US10555894B2 (en) | Plant extract comprising sucrose esters as an active agent for use in cosmetic, dermatological or nutricosmetic composition | |
WO2017217695A1 (en) | Composition comprising alpha-garcinia mangostana, beta-garcinia mangostana, gamma-garcinia mangostana, or gartanin compound as effective ingredient for improving skin wrinkle or for moisturizing skin | |
WO2022191551A1 (en) | Composition comprising cannabigerol | |
WO2013077569A1 (en) | Topical skin treatment composition comprising dendranthema indicum extract | |
WO2013115456A1 (en) | Food, cosmetic material, or pharmaceutical composition containing ginger supercritical extract and fermented dropwort residue extract | |
KR101430636B1 (en) | Functional cosmetic composition comprising ginsenosides Rh2 and Rg3 | |
JP3998085B2 (en) | Hyaluronic acid amount increase accelerator | |
KR102024572B1 (en) | External composition for skin containing Ginsenoside Rf | |
KR102525579B1 (en) | Composition for protecting skin comprising extract of Oryza Sativa(Rice), Phragmites Communis, Zea Mays(Corn) Silk, Malva Sylvestris(Mallow) and Aloe Barbadensis as active ingredient | |
KR20090085844A (en) | Cosmetic composition containing natural medicinal plant extract for alleviating skin inflammation | |
WO2016171482A1 (en) | Cosmetic composition including apitoxin extract, and method of manufacturing same | |
KR20200104450A (en) | Cosmetic composition containing phycocyanobilin and its derivative derived from spirulina | |
KR102676799B1 (en) | External Composition Comprising Natural Complex Extract for Improving Skin | |
KR100516378B1 (en) | Compositions comprising alcohol extract of pueraria root |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22767447 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |